If you made any changes in Pure these will be visible here soon.

Personal profile


Daniel Gough is a biochemist and cancer biologist and the head of the STAT Cancer Biology laboratory in the Centre for Cancer Research at the Monash Institute of Medical Research. Daniel's research focuses on signal transduction pathways which engage the Signal Transducer and Activator of Transcription (STAT) proteins in normal development and how these pathways are altered in childhood cancers.

After completing his B.Sc (2000), B.Sc(Hons) (2001) in the Department of Pathology at the University of Melbourne, and Ph.D (2006) at the Peter MacCallum Cancer Centre, Daniel moved to New York University in the U.S.A for post doctoral training with Professor David E Levy (Dr. Louis A. Schneider Professor of Molecular Pathology and Professor of Microbiology and Associate Dean for Collaborative Science). During this time Daniel defined a mitochondrial and metabolic role for STAT3 which is necessary for cancers driven by Ras mutation. In 2012 Daniel was recruited to return to Australia to start his laboratory.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2010 2022

Research Output 2003 2019

  • 25 Article
  • 3 Review Article
  • 1 Chapter (Book)
  • 1 Comment / Debate

Serine-phosphorylated STAT3 promotes tumorigenesis via modulation of RNA polymerase transcriptional activity

Balic, J. J., Garama, D. J., Saad, M. I., Yu, L., West, A. C., West, A. J., Livis, T., Bhathal, P. S., Gough, D. J. & Jenkins, B. J., 15 Oct 2019, In : Cancer Research. 79, 20, p. 5272-5287 16 p.

Research output: Contribution to journalArticleResearchpeer-review

35 Citations (Scopus)

Therapeutically exploiting STAT3 activity in cancer — using tissue repair as a road map

Huynh, J., Chand, A., Gough, D. & Ernst, M., 1 Feb 2019, In : Nature Reviews Cancer. 19, 2, p. 82-96 15 p.

Research output: Contribution to journalReview ArticleResearchpeer-review

3 Citations (Scopus)

Toll-like receptor 2 regulates metabolic reprogramming in gastric cancer via superoxide dismutase 2

Liu, Y. D., Yu, L., Ying, L., Balic, J., Gao, H., Deng, N. T., West, A., Yan, F., Ji, C. B., Gough, D., Tan, P., Jenkins, B. J. & Li, J. K., 15 Jun 2019, In : International Journal of Cancer. 144, 12, p. 3056-3069 14 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
8 Citations (Scopus)

A phase IIa study of HA-irinotecan, formulation of hyaluronic acid and irinotecan targeting CD44 in extensive-stage small cell lung cancer

Alamgeer, M., Neil Watkins, D., Banakh, I., Kumar, B., Gough, D. J., Markman, B. & Ganju, V., 1 Apr 2018, In : Investigational New Drugs. 36, 2, p. 288-298 11 p.

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)

Deep multi-region whole-genome sequencing reveals heterogeneity and gene-by-environment interactions in treatment-naive, metastatic lung cancer

Leong, T. L., Gayevskiy, V., Steinfort, D. P., De Massy, M. R., Gonzalez-Rajal, A., Marini, K. D., Stone, E., Chin, V., Havryk, A., Plit, M., Irving, L. B., Jennings, B. R., McCloy, R. A., Jayasekara, W. S. N., Alamgeer, M., Boolell, V., Field, A., Russell, P. A., Kumar, B., Gough, D. J. & 8 others, Szczepny, A., Ganju, V., Rossello, F. J., Cain, J. E., Papenfuss, A. T., Asselin-Labat, M. L., Cowley, M. J. & Watkins, D. N., 7 Mar 2018, In : Oncogene. 38, 10, p. 1661-1675 15 p.

Research output: Contribution to journalArticleResearchpeer-review